Jin10 data reported on October 13 that Chenguang Biotech announced that it expects the net profit attributable to shareholders of the listed company for the first three quarters of 2025 to be between 278 million yuan and 314 million yuan, an increase of 344.05% to 401.55% compared to the same period last year. In the first three quarters of 2025, the revenue and gross profit of major plant extraction products achieved year-on-year growth, restoring profitability; the market for cottonseed-related businesses has warmed up, and the operating environment has significantly improved, achieving a return to profitability year-on-year, with the overall performance of the company rising compared to the same period last year.
Disclaimer: The information on this page may come from third parties and does not represent the views or opinions of Gate. The content displayed on this page is for reference only and does not constitute any financial, investment, or legal advice. Gate does not guarantee the accuracy or completeness of the information and shall not be liable for any losses arising from the use of this information. Virtual asset investments carry high risks and are subject to significant price volatility. You may lose all of your invested principal. Please fully understand the relevant risks and make prudent decisions based on your own financial situation and risk tolerance. For details, please refer to
Disclaimer.
